Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor
Autore:
Wan, XS; Meyskens, FL; Armstrong, WB; Taylor, TH; Kennedy, AR;
Indirizzi:
Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA Univ Penn Philadelphia PA USA 19104 iat Oncol, Philadelphia, PA 19104 USA Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Dept Med, Orange, CA USA Univ Calif Irvine Orange CA USA ehens Canc Ctr, Dept Med, Orange, CA USA Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Dept Otorhinolaryngol,Orange, CA USA Univ Calif Irvine Orange CA USA tr, Dept Otorhinolaryngol,Orange, CA USA
Titolo Testata:
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
fascicolo: 7, volume: 8, anno: 1999,
pagine: 601 - 608
SICI:
1055-9965(199907)8:7<601:RBPAAN>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; OVARIAN-CANCER; BREAST-CANCER; EGF RECEPTOR; EXTRACELLULAR DOMAIN; C-ERBB-2 ONCOPROTEIN; PROTO-ONCOGENE; TUMOR-MARKERS; SERUM LEVELS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
47
Recensione:
Indirizzi per estratti:
Indirizzo: Wan, XS Univ Penn, Sch Med, Dept Radiat Oncol, 195 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA Univ Penn 195 John Morgan Bldg,3620 Hamilton Walk Philadelphia PA USA 19104
Citazione:
X.S. Wan et al., "Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor", CANC EPID B, 8(7), 1999, pp. 601-608

Abstract

The protease catalyzing the hydrolysis of the tripeptide fluorescence substrate, butoxycarbonyl-valine-proline-arginine-(7-amino-4-methylcoumarin) (Boc-Val-Pro-Arg-MCA) and the neu oncogenic protein are potentially useful biomarkers for human cancer prevention studies. In the present study, we standardized a specific substrate hydrolysis method for measuring this proteaseactivity in human oral mucosal cells and characterized the relationship between neu oncogene expression and protease activity in patients enrolled inan oral cancer prevention trial using Bowman Birk Inhibitor Concentrate (BBIC) as the cancer preventive agent. The results demonstrate that changes in the protease activity in oral mucosal cells after BBIC treatment correlated with the changes in the neu protein levels in oral mucosal cells (r = 0.726, P < 0.001) and serum (r = 0.675, P < 0.001), suggesting that the Boc-Val-Pro-Arg-MCA hydrolyzing activity can be as useful as neu oncogene expression as a cancer biomarker, In the 25 patients enrolled in the study, the level of neu protein in oral mucosal cells correlated with the serum neu protein concentration in the patients before BBIC treatment (r 0.645, P < 0.001), However, such a correlation was not observed after the BBIC treatment, suggesting that BEI may inhibit serine protease(s) involved in the cleavageof neu protein on the cell surface, thereby preventing the release of the extracellular domain of neu protein into the circulation. By inhibiting thecleavage of neu protein on the cell surface, BBI could prevent malignant and premalignant cells expressing high levels of neu protein antigen from escaping host immunological surveillance control.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/08/20 alle ore 22:50:46